Physician’s declaration
<!--Your terms and conditions content goes here.
-->
agent with broad-spectrum antiviral properties.
Introducing Viralex®
Viralex® (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body’s defence response to viral infections. It has been proven to positively impact the host’s immune system, by enhancing T-cell lymphocyte proliferation and activity of natural killer cells, increasing levels of pro-inflammatory cytokines, and thereby restoring deficient responses in immunosuppressed patients.
At the same time, it has been shown that it can affect viral RNA levels and hence inhibit growth of several viruses. Due to its immunomodulatory and antiviral properties, and its safety profile, it has been widely used from last 50 years against various viral infections in more than 70 countries including the UK. Japan, Canada and many European countries.
VIRALEX®
A well Established Medicine Globally
Inosine Pranobex
It has been approved in >70 countries over last 50 years. Its legal re-classification from POM to OTC category in some countries further reiterates its efficacy & safety
Body's Immune response
Inosine pranobex acts by strengthening body’s immune response to viral infections, and also inhibits viral replication by slowing down viral mRNA synthesis.
Efficacy and Safety
Human PK, PD and clinical efficacy and safety has been established in numerous clinical trials in different indications, dose ranges, and in different patient population.
New Ray of Hope
It enhances host immunity, It is an effective medicine with an established safety profile and will offer a much-needed therapeutic solution to fight COVID-19.
Product Benefits.
Knowledge centre
Based on the promising study results, the drug appears to offer immense clinical benefit to the patients in the early stages of COVID-19, thus reducing the load on the health care system.
Viralex Press release
Why it Works
Experts Speak
Dr Raja Dhar
Director and Head of Department of Pulmonology, C K Birla Hospitals,
“Inosine Pranobex is a drug which enhances host immunity (immunomodulatory effect) & can affect viral RNA and hence inhibits growth of several viruses. Phase 3 Double blind RCTs are rare in COVID 19. I am heartened to hear that Themis Medicare has come up with such a trial, which shows early clinical response and shortened period of recovery when used in mild to moderate COVID 19 cases. This drug, if successfully used in clinical practice would considerably reduce the burden on health care system."
Dr. Ashok Swain
Head Clinical Development,Themis Medicare Ltd.
“VIRALEX® is a new ray of hope in these challenging times,”
Dr. Sachin Patel,
Managing Director& CEO of Themis Medicare Ltd.
“Our endeavor has always been to develop medicines that benefit patients and make healthcare far, far more effective. Due to the frequently mutating trend of the virus, the uncertainties of the
pandemic continue. We hope access to effective treatment such as VIRALEX® will
offer a much-needed therapeutic solution, and if initiated early in the disease, it
would reduce the load on the health care system”
About Inosine Pranobex
Inosine pranobex has been approved in >70 countries for treatment of various viral infections with continued positive benefit vs. risk profile over last 50 years. Its legal re-classification from POM to OTC category in some countries further reiterates its efficacy & safety, indicating it as a “Well Established Medicine”.
Human PK, PD and clinical efficacy and safety has been established in numerous clinical trials in different indications, dose ranges, and in different patient population.
Inosine pranobex acts by strengthening body’s immune response to viral infections, and also inhibits viral replication by slowing down viral mRNA synthesis.
Data from various studies in more than 800 COVID-19 patients confirm that it produced earlier clinical improvement and cure in significantly higher number of patients when added to the standard of care in patients with mild to moderate COVID-19, and reduced case fatality rate in elderly patients.
Soon to be introduced in India as a ‘Prescription Only Medicine (POM)’ as Viralex® 500mg tablets.
Due to the frequently mutating trend of the virus, the uncertainties of the pandemic continue. Viralex® is a new ray of hope in these challenging times. It enhances host immunity and continues to provide its beneficial effect to fight viral infections. It is an effective medicine with an established safety profile and will offer a much-needed therapeutic solution to address the unmet need in the management of COVID-19.
About the Parent Organisation
50 years of excellence in Pain Management and Critical Care
Themis is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives. We develop high response differentiated products through our platform technologies with a clear focus on patient benefit.
Our vision is to develop medicines that benefit patients and make healthcare far, far more effective.
“VIRALEX® is a new ray of hope in these challenging times,”
Dr. Ashok Swain
Head Clinical Development,Themis Medicare Ltd.